These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 17254822

  • 1. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T, Padilla A.
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [Abstract] [Full Text] [Related]

  • 2. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B, Arrabal S.
    Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
    [Abstract] [Full Text] [Related]

  • 3. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A, Ironside JW, Giangrande P.
    Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
    [Abstract] [Full Text] [Related]

  • 4. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
    Ironside JW, Head MW.
    Haemophilia; 2004 Oct; 10 Suppl 4():64-9. PubMed ID: 15479374
    [Abstract] [Full Text] [Related]

  • 5. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
    Berardi VA, Cardone F, Valanzano A, Lu M, Pocchiari M.
    Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
    [Abstract] [Full Text] [Related]

  • 6. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease.
    Cervia JS, Sowemimo-Coker SO, Ortolano GA, Wilkins K, Schaffer J, Wortham ST.
    Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827
    [Abstract] [Full Text] [Related]

  • 7. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
    Ludlam CA, Turner ML.
    Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transfusion transmission of human prion diseases.
    Zou S, Fang CT, Schonberger LB.
    Transfus Med Rev; 2008 Jan; 22(1):58-69. PubMed ID: 18063192
    [Abstract] [Full Text] [Related]

  • 16. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies.
    Beisel CE, Morens DM.
    Clin Infect Dis; 2004 Mar 01; 38(5):697-704. PubMed ID: 14986255
    [Abstract] [Full Text] [Related]

  • 17. [Transmissible spongiform encephalopathies--illnesses in the human].
    Budka H.
    Wien Med Wochenschr; 1998 Mar 01; 148(4):86-95. PubMed ID: 9611348
    [Abstract] [Full Text] [Related]

  • 18. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy.
    Brown P.
    Haemophilia; 2007 Dec 01; 13 Suppl 5():33-40. PubMed ID: 18078395
    [Abstract] [Full Text] [Related]

  • 19. Selection of spiking materials for studies on the clearance of agents of transmissible spongiform encephalopathy during plasma fractionation.
    Foster PR.
    Biologicals; 2008 Mar 01; 36(2):142-3. PubMed ID: 17400473
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.